logo
logo
logo
MENU
Categories
Hospitals and Health Systems - Audits and ReimbursementHospitals and Health Systems - Consent and TreatmentHospitals and Health Systems - Corporate and GovernanceHospitals and Health Systems - Corporate ComplianceHospitals and Health Systems - Fraud and AbuseHospitals and Health Systems - Government InvestigationsHospitals and Health Systems - Health RecordsHospitals and Health Systems - HIPAA and HITECHHospitals and Health Systems - Managed CareHospitals and Health Systems - Medical Staff IssuesHospitals and Health Systems - Medical Training ProgramsHospitals and Health Systems - MedicareHospitals and Health Systems - Mergers, Affiliations and Joint VenturesHospitals and Health Systems - Peer ReviewHospitals and Health Systems - Professional Services AgreementsMedical SocietiesPharmaceutical Industry - Agreements with PhysiciansPharmaceutical Industry - Clinical ResearchPharmaceutical Industry - Regulatory CompliancePhysicians and Providers - Audits and ReimbursementPhysicians and Providers - CertificationsPhysicians and Providers - CredentialingPhysicians and Providers - Disciplinary ActionsPhysicians and Providers - Employment AgreementsPhysicians and Providers - Fraud and AbusePhysicians and Providers - Government InvestigationsPhysicians and Providers - HIPAA and PrivacyPhysicians and Providers - ImpairmentPhysicians and Providers - LicensingPhysicians and Providers - LitigationPhysicians and Providers - MedicarePhysicians and Providers - Peer ReviewPhysicians and Providers - Practice AcquisitionsPhysicians and Providers - Practice IssuesPhysicians and Providers - Regulatory CompliancePhysicians and Providers - SupervisionPhysicians and Providers - TrainingUncategorized
F. Peter Lehr
Member
F. Peter Lehr
Visit Profile

CMS Establishes New Rules for Payment of COVID-19 Vaccine

COVID-19 Testing, Treatment, and Vaccine- HIPAA Compliance

On October 28, 2020, the Centers for Medicare & Medicaid Services (CMS) issued an interim final rule with a comment period, the fourth such issuance during the COVID-19 public health emergency, in anticipation of vaccine availability in the near future. Effective immediately, these provisions will continue through the duration of the emergency.

COVID-19 Vaccine

The Coronavirus Aid, Relief, and Economic Security (CARES) Act established Medicare Part B coverage and payment for the COVID-19 vaccine and its administration. The interim rule authorizes Part B coverage for all vaccines that receive approval by the FDA or an Emergency Use Authorization by the Commissioner of Food and Drugs. Any such vaccine, and its administration, will be added to the list of preventive vaccines covered under Part B without coinsurance or deductible.

The interim rule also includes provisions for implementing the CARES Act requirement that non-grandfathered group health plans, as well as health insurance issuers offering non-grandfathered group or individual health insurance coverage, must provide coverage, without cost sharing, for qualifying COVID-19 preventive services including vaccines, regardless of whether an in-network or out-of-network provider delivers the services. State Medicaid and CHIP programs, too, must provide COVID-19 vaccines and their administration for most beneficiaries without cost sharing.

To mitigate potential financial disincentives for hospitals to provide innovative COVID-19 treatment, the interim rule provides enhanced payments for eligible inpatient cases where certain new authorized or approved products are used. The enhanced payment will equal the lesser of 65% of the operating outlier threshold for the claim OR 65% of the cost of a COVID-19 stay beyond the operating Medicare payment (including the 20% add-on payment under Section 3710 of the CARES Act) for eligible cases.

COVID-19 Treatment

Similarly, the CMS will incentivize the use of new COVID-19 treatments provided in hospital outpatient settings. For the duration of the public health emergency, the CMS will exclude FDA authorized or approved drugs and biologicals that treat or prevent COVID-19 from being packaged into the Comprehensive Ambulatory Payment Classification (C-APC) payment when these treatments are billed on the same claim as a primary C-APC service. Instead, such drugs and biologicals may be billed and will be paid by Medicare separately.

In response to the CARES Act requirement for price transparency, the CMS added a new rule applicable to every provider of a COVID-19 diagnostic test, which is codified at 45 C.F.R. Part 182. Each provider must publish on its website the cash price, defined as the charge that applies to an individual who pays cash (or cash equivalent) for a COVID-19 diagnostic test. Any provider that does not have its own website must make the cash price available in writing within two business days, upon request, and through signage (if applicable). If the CMS determines that a provider is non-compliant, it may:

  • Provide a written warning;
  • If compliance does not occur after the warning, solicit a corrective action plan from the provider; and
  • Ultimately impose a civil monetary penalty in the event of a failure to submit, or comply with, a corrective action plan.

If you have any questions or would like assistance to better understand any of the CMS rules, please contact plehr@norris-law.com. For more topics related to COVID-19, visit our Coronavirus Thought Leadership Connection.

The information contained in this post may not reflect the most current developments, as the subject matter is extremely fluid and constantly changing. Please continue to monitor this site for ongoing developments. Readers are also cautioned against taking any action based on information contained herein without first seeking advice from professional legal counsel.

Share
Related Posts
OSHA Issues COVID-19 Safety Rule: Emergency Temporary Standard (ETS)
Impact of the COVID Pandemic on Physician Employment Agreements
Telemedicine and the COVID-19 Vaccination – What’s on the Horizon for 2021?
F. Peter Lehr
Member
F. Peter Lehr
Visit Profile
Related Posts
OSHA Issues COVID-19 Safety Rule: Emergency Temporary Standard (ETS)
Impact of the COVID Pandemic on Physician Employment Agreements
Telemedicine and the COVID-19 Vaccination – What’s on the Horizon for 2021?
Share
Join our growing team
We are looking for quality attorneys to help us do more for our clients. At Norris McLaughlin, each attorney has the same opportunity to succeed whether you’re at the beginning of a career or pinnacle of the profession.
Subscribe to our content
Receive timely legal information
delivered to your inbox
Subscribe to our content
Receive timely legal information
delivered to your inbox
© 2021, Norris McLaughlin, P.A., All Rights Reserved. Attorney Advertising.
Meritas

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume you consent to our cookie policy. Learn more